GBB
AI Biomedical R&D Company
Hong Kong
January 21, 2025
Recently,GBB Collaborates with Professor Chen from the Koch Institute for Integrative Cancer Research at MIT to Focus on the Discovery of Tumor Neoantigen Antibodies, Providing Innovative Antibody Drug Molecule Solutions for the Treatment of Various Solid Tumors.This collaboration marks a new height in the application of GBB's international cutting-edge biotechnology.
This project collaboration combines GBB's application advantages in the field of drug discovery with MIT Research Institute’s profound expertise in tumor antibody research, bioscience, medicine, and computer science, jointly promoting the discovery of new antibodies for tumor antigens and rapidly developing novel therapeutic solutions for various solid tumors.
GBB is a high-tech biotechnology company that leverages cutting-edge technologies such as artificial intelligence, big data mining, and automation to drive drug development, adhering to the corporate vision of "making global bioprocess development simpler and more efficient." In its internationalization process, GBB has established collaborations with several multinational giants in the fields of life sciences, specialty chemicals, and pharmaceutical CDMOs. Additionally, AlfaCell, the world’s first commercially available targeted integration cell line construction platform developed by Great Bay Bio, has helped clients obtain approval from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) applications.
Professor Chen graduated from Stanford University in the United States and serves as a professor of biology at the Massachusetts Institute of Technology, a research professor in Singapore, and a researcher at the Koch Institute. He is dedicated to studying the immune system and its applications in cancer immunotherapy and vaccine development. Professor Chen has extensive research experience in immunology, molecular and cellular mechanisms, humanized mice, innovative compounds, and target discovery. Dr. Chen has published numerous professional papers in authoritative journals such as Nature, Nature Biomedical Engineering, and Cell. In recognition of his outstanding contributions to scientific research, technological innovation, education, and public service, he has been honored with the title of Fellow of the American Association for the Advancement of Science (AAAS).
Professor Chen stated, "The goal of our laboratory is to deeply explore efficient and diverse cancer treatment methods. GBB has extensive experience in intelligent drug development. We hope this collaboration will promote breakthrough progress in our laboratory's research on antibody drug molecules. Through close cooperation with GBB, we will continuously innovate to provide effective rehabilitation solutions for cancer patients."
END
Great Bay Bio Partners with Prof Chen from MIT to Co-develop Novel Tumor Antibody
Hong Kong
January 21, 2025
Recently, Great Bay Bio (GBB) partnered with Professor JZ Chen from the Koch Institute for Integrative Cancer Research at MIT to advance the discovery of a novel tumor-targeting antibody. This partnership aims to provide innovative antibody drug solutions for treating multiple solid tumors. This collaboration marks a new milestone for GBB in the application of cutting-edge international biotechnology.
This collaboration combines GBB's applied advantages in the field of drug discovery with the extensive expertise of Professor Chen in tumor-specific antibody discovery. Together, we aim to drive the discovery of novel antibodies targeting tumor antigens and accelerate the development of innovative therapeutic solutions for various solid tumors.
GBB is a biotech company that drives drug development using advanced technologies such as AI, big data mining, and automation, with a vision of “Global Bioprocessing Made Simpler and More efficient." In the process of internationalization, GBB has established partnerships with several MNCs in the life sciences, specialty chemicals, and pharmaceutical CDMO sectors. Additionally, GBB has launched the world’s first commercialized site-specific integration cell line development platform (AlfaCell), which has enabled customers to secure clinical trial approvals from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).
Professor Chen is professor of biology at MIT, Singapore Research Professor, and intramural faculty at the Koch Institute. He is dedicated to studying the immune system and its applications in cancer immunotherapy and vaccine development. He has extensive research experience in immunology, molecular and cellular mechanisms, humanized mice, and target discovery, and antibody-mediated therapies. Professor Chen has published numerous scholarly papers in prestigious journals such as Nature, Nature Biomedical Engineering, and Cell. Professor Chen was elected as Fellow by the American Association for the Advancement of Science (AAAS) for his outstanding contributions to scientific research, technological innovation, education, and public service.
Professor Chen stated, “Our laboratory aims to deeply explore efficient and diverse tumor treatment approaches. By leveraging Great Bay Bio’s extensive expertise in intelligent drug development, this collaboration will drive groundbreaking progress in the field of tumor-specific antibodydiscovery, providing cancer patients with more effective treatment solutions.”
END